share_log

Adial Pharmaceuticals | EFFECT: Others

SEC ·  Jan 25 19:04
Summary by Futu AI
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of January 24, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of January 24, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.